Peroxisome proliferator-activated receptor α protects against obesity-induced hepatic inflammation

Endocrinology

Volumn 148, Issue 6, 2007, Pages 2753-2763

  Stienstra, Rinke ^a,b   Mandard, Stéphane ^a   Patsouris, David ^a   Maass, Cathy ^c   Kersten, Sander ^a,b   Müller, Michael ^a,b  

^a WAGENINGEN UNIVERSITY   (Netherlands)

^b TOP INSTITUTE FOOD AND NUTRITION   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PIRINIXIC ACID; TRIACYLGLYCEROL;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; FATTY LIVER; GENE AMPLIFICATION; GENE EXPRESSION; HEPATITIS; IN VITRO STUDY; IN VIVO STUDY; KNOCKOUT MOUSE; LIPID DIET; LOW FAT DIET; MALE; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR UPREGULATION;

ADIPOSE TISSUE; ANIMALS; CELLS, CULTURED; DIET, ATHEROGENIC; DIET, FAT-RESTRICTED; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HEPATITIS, ANIMAL; LIVER; MALE; MICE; MICE, KNOCKOUT; OBESITY; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PPAR ALPHA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRIGLYCERIDES;

EID: 34250821923     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2007-0014     Document Type: Article

References (35)

1. Desvergne B, Wahli W 1999 Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 20:649-688
2. Knouff C, Auwerx J 2004 Peroxisome proliferator-activated receptor-γ calls for activation in moderation: lessons from genetics and pharmacology. Endocr Rev 25:899-918
3. Luquet S, Lopez-Soriano J, Holst D, Gaudel C, Jehl-Pietri C, Fredenrich A, Grimaldi PA 2004 Roles of peroxisome proliferator-activated receptor δ (PPARδ) in the control of fatty acid catabolism. A new target for the treatment of metabolic syndrome. Biochimie (Paris) 86:833-837
4. Mandard S, Muller M, Kersten S 2004 Peroxisome proliferator-activated receptor α target genes. Cell Mol Life Sci 61:393-416
5. Vanden Berghe W, Vermeulen L, Delerive P, De Bosscher K, Staels B, Haegeman G 2003 A paradigm for gene regulation: inflammation, NF-κB and PPAR. Adv Exp Med Biol 544:181-196
6. Delerive P, De Bosscher K, Besnard S, Vanden Berghe W, Peters JM, Gonzalez FJ, Fruchart JC, Tedgui A, Haegeman G, Staels B 1999 Peroxisome proliferator-activated receptor α negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-κB and AP-1. J Biol Chem 274:32048-32054
7. Gervois P, Kleemann R, Pilon A, Percevault F, Koenig W, Staels B, Kooistra T 2004 Global suppression of IL-6-induced acute phase response gene expression after chronic in vivo treatment with the peroxisome proliferator-activated receptor-α activator fenofibrate. J Biol Chem 279:16154-16160
8. Dandona P, Aljada A, Bandyopadhyay A 2004 Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 25:4-7
9. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA, Chen H 2003 Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 112:1821-1830
10. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante Jr AW 2003 Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112:1796-1808
11. Trayhurn P, Wood IS 2004 Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 92:347-355
12. Maachi M, Pieroni L, Bruckert E, Jardel C, Fellahi S, Hainque B, Capeau J, Bastard JP 2004 Systemic low-grade inflammation is related to both circulating and adipose tissue TNFα, leptin and IL-6 levels in obese women. Int J Obes Relat Metab Disord 28:993-997
13. Arkan MC, Hevener AL, Greten FR, Maeda S, Li ZW, Long JM, Wynshaw-Boris A, Poli G, Olefsky J, Karin M 2005 IKK-β links inflammation to obesity-induced insulin resistance. Nat Med 11:191-198
14. Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J, Shoelson SE 2005 Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB. Nat Med 11:183-190
15. Liu X, Milo M, Lawrence ND, Rattray M 2005 A tractable probabilistic model for Affymetrix probe-level analysis across multiple chips. Bioinformatics 21:3637-3644
16. Dai M, Wang P, Boyd AD, Kostov G, Athey B, Jones EG, Bunney WE, Myers RM, Speed TP, Akil H, Watson SJ, Meng F 2005 Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Res 33:e175
17. Kuipers F, Jong MC, Lin Y, Eck M, Havinga R, Bloks V, Verkade HJ, Hofker MH, Moshage H, Berkel TJ, Vonk RJ, Havekes LM 1997 Impaired secretion of very low density lipoprotein-triglycerides by apolipoprotein E-deficient mouse hepatocytes. J Clin Invest 100:2915-2922
18. Glibetic MD, Baumann H 1986 Influence of chronic inflammation on the level of mRNA for acute-phase reactants in the mouse liver. J Immunol 137:1616-1622
19. Mackay CR 2001 Chemokines: immunology's high impact factors. Nat Immunol 2:95-101
20. Rot A, von Andrian UH 2004 Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Annu Rev Immunol 22:891-928
21. Leenen PJ, de Bruijn MF, Voerman JS, Campbell PA, van Ewijk W 1994 Markers of mouse macrophage development detected by monoclonal antibodies. J Immunol Methods 174:5-19
22. Yu S, Rao S, Reddy JK 2003 Peroxisome proliferator-activated receptors, fatty acid oxidation, steatohepatitis and hepatocarcinogenesis. Curr Mol Med 3:561-572
23. Wellen KE, Hotamisligil GS 2005 Inflammation, stress, and diabetes. J Clin Invest 115:1111-1119
24. Powell EE, Jonsson JR, Clouston AD 2005 Steatosis: co-factor in other liver diseases. Hepatology 42:5-13
25. Ip E, Farrell GC, Robertson G, Hall P, Kirsch R, Leclercq I 2003 Central role of PPARα-dependent hepatic lipid turnover in dietary steatohepatitis in mice. Hepatology 38:123-132
26. Ip E, Farrell G, Hall P, Robertson G, Leclercq I 2004 Administration of the potent PPARα agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice. Hepatology 39:1286-1296
27. Devchand PR, Keller H, Peters JM, Vazquez M, Gonzalez FJ, Wahli W 1996 The PPARα-leukotriene B4 pathway to inflammation control. Nature 384:39-43
28. Nakajima T, Kamijo Y, Tanaka N, Sugiyama E, Tanaka E, Kiyosawa K, Fukushima Y, Peters JM, Gonzalez FJ, Aoyama T 2004 Peroxisome proliferator-activated receptor α protects against alcohol-induced liver damage. Hepatology 40:972-980
29. Romics Jr L, Kodys K, Dolganiuc A, Graham L, Velayudham A, Mandrekar P, Szabo G 2004 Diverse regulation of NF-κB and peroxisome proliferator-activated receptors in murine nonalcoholic fatty liver. Hepatology 40:376-385
30. Li AC, Binder CJ, Gutierrez A, Brown KK, Plotkin CR, Pattison JW, Valledor AF, Davis RA, Willson TM, Witztum JL, Palinski W, Glass CK 2004 Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARα, β/δ, and γ. J Clin Invest 114:1564-1576
31. Kleemann R, Verschuren L, de Rooij BJ, Lindeman J, de Maat MM, Szalai AJ, Princen HM, Kooistra T 2004 Evidence for anti-inflammatory activity of statins and PPARα activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro. Blood 103:4188-4194
32. 1 switch gene 2 is a novel PPAR target gene. Biochem J 392:313-324
33. Luster AD 1998 Chemokines - chemotactic cytokines that mediate inflammation. N Engl J Med 338:436-445
34. Su GL 2002 Lipopolysaccharides in liver injury: molecular mechanisms of Kupffer cell activation. Am J Physiol Gastrointest Liver Physiol 283:G256-G265
35. Patsouris D, Reddy JK, Muller M, Kersten S 2006 Peroxisome proliferator-activated receptor α mediates the effects of high-fat diet on hepatic gene expression. Endocrinology 147:1508-1516